Accessibility Menu
Vigil Neuroscience logo

Vigil Neuroscience(NASDAQ) VIGL

This security has been delisted. This page is retained for historical reference.

Vigil Neuroscience last closing stock price
MetricPriceDate
Last closeUSD 8.052025-08-04
Vigil Neuroscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.12%USD 8.062025-07-28
1 month+0.75%USD 7.992025-07-03
3 month+234.02%USD 2.412025-05-06
Year to date+373.53%USD 1.702024-12-31
1 year+103.8%USD 3.952024-08-02
3 year+3.87%USD 7.752022-08-05
Since inception-36.36%USD 12.652022-01-07

VIGL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

VIGL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-92.27%

Return on Capital

-106.03%

Return on Assets

-56.61%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$12.00K

Operating Income

-$96.75M

EBITDA

-$95.21M

Operating Cash Flow

-$58.21M

Capital Expenditure

-$354.00K

Free Cash Flow

-$58.57M

Cash & ST Invst.

$66.99M

Total Debt

$12.44M

Vigil Neuroscience Performance Analysis

Vigil Neuroscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Vigil Neuroscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30N/A
Vigil Neuroscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -28.26N/A
20222022-12-31USD -2.16-92.4%
20232023-12-31USD -2.13-1.0%
20242024-12-31USD -2.07-2.9%
Vigil Neuroscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-309.6%
Q42024-12-31-21.3%
Q12025-03-3114.0%
Q22025-06-30-14.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

69

N/A

Net Income

-$26.66M

-25.6%

EBITDA

-$27.36M

-22.3%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$66.99M

-22.7%

Total Debt

$12.44M

-7.2%

Accounts Receivable

$558.00K

+5.3%

Inventory

$0.00

N/A

Long Term Debt

$11.33M

-8.9%

Short Term Debt

$2.21M

+128.3%

Return on Assets

-56.61%

N/A

Return on Invested Capital

-96.91%

N/A

Free Cash Flow

-$20.55M

-32.5%

Operating Cash Flow

-$20.48M

-32.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORTXOrchard Therapeutics plc
$16.70+0.30%
CKPTCheckpoint Therapeutics, Inc.
$4.26+0.00%
RVNCRevance Therapeutics, Inc.
$3.65+0.00%
GTHXG1 Therapeutics, Inc.
$7.16+0.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.07%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.77+0.01%
AALAmerican Airlines Group
$14.47+0.07%
MARAMara Holdings
$12.62-0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.